SLNO (Soleno Therapeutics) Short-Term Debt to Capital

Corporate company logo of Soleno Therapeutics (SLNO)

High research costs and stringent FDA oversight create significant barriers to entry for new players in the orphan drug niche. This chart of current share prices reflects a debt-to-equity ratio of 0.00. Soleno Therapeutics (SLNO) relies on developing therapies for individuals with Prader-Willi syndrome, yet a critical dependence on a single drug creates substantial binary risks for investors.

Ratio of Short-Term Indebtedness to Capital: Soleno (SLNO) for 07/04/2022 - 05/30/2026

Analytical breakdowns for Soleno Therapeutics

- stock quotes and analyst forecast:
Stock Price Soleno|SLNO - Fair Value Consensus
- business market valuation indicators:
Market Capitalization Soleno Therapeutics Inc|SLNO - Enterprise Value
- book capitalization information:
Net Assets per Single Share Soleno Therapeutics|SLNO - Accounting Value of Company|Market Value to Book Value Ratio soleno.life|SLNO - Cumulative Company Assets
- company liabilities and liquidity data:
Total Debt to Capital Soleno Therapeutics|SLNO - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Soleno Therapeutics, Inc.|SLNO - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Soleno Therapeutics Inc|SLNO - Company Long-Term Liabilities|Company Short-Term Debts Soleno Therapeutics|Quick Liquidity Indicator soleno.life
- company profitability and valuation multiples indicators:
SLNO - Profit After Payment of Taxes
Fundamental valuation:SLNO Soleno
Brand item of Soleno Therapeutics Inc

The biopharmaceutical model of Soleno Therapeutics (SLNO) currently relies on immense trust from the medical community and the success of clinical trials. By analyzing the short-term debt-to-market cap chart, an investor assesses the proportion of liabilities due within one year relative to equity, which helps determine liquidity risk and the company's resilience to default during a period of aggressive growth and high market expectations.

Competitors of Soleno Therapeutics

Short-Term Debt to Capital ASND|MDGL (Madrigal Corp) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital CORT (Corcept Therapeutics)|Short-Term Debt to Capital rhythmtx.com RYTM|AKRO - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital MTSR (Metsera, Inc.)|MoonLake Pharma (MLTX) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Crinetics Corp|NAMS (NewAmsterdam Pharma) - Short-Term Debt to Capital|Short-Term Debt to Capital amicusrx.com|Short-Term Debt to Equity Ratio ETNB (89bio)|AGIO (Agios) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Structure Pharma GPCR|MDXG - Short-Term Debt to Equity Ratio|Rezolute, Inc. - Short-Term Debt to Capital|Current Liabilities to Capital lexpharma.com|MBX (MBX Biosciences) - Short-Term Debt to Equity Ratio|ALT: Short-Term Loans to Capital Ratio|AARD (Aardvark Therapeutics Corp) - Short-Term Debt to Capital|Short-Term Debt to Capital Sagimet Biosciences Inc|Short-Term Debt to Capital BIOA|Short-Term Debt to Equity BMEA (biomeafusion.com)|Short-Term Debt to Equity Quince Therapeutics, Inc. QNCX|Fractyl Health Inc. (GUTS) - Current Liabilities to Capital|VTVT - Short-Term Debt to Equity|ATPC: Short-Term Debt to Equity|PLUR: Short-Term Debt to Capital|SYBX - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Lipocine|Matinas BioPharma Holdings Inc. (MTNB) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Spruce Biosciences (SPRB)|Short-Term Debt to Equity Ratio Galecto Corporation GLTO|Short-Term Debt to Equity Carmell Corporation CTCX|Short-Term Debt to Capital Coefficient lumos-pharma.com (LUMO)|ONVO - Short-Term Debt to Equity|Current Liabilities to Capital Radius Recycling Inc.